Northwest Biotherapeutics CTO to Keynote UK NHS Oncology Conference

The presentation, titled "Harnessing Immunity: A Personalised, Multi-Target Approach to Cancer," arrives as the company navigates the regulatory review process for its DCVax-L treatment for glioblastoma. Dr. Bosch plans to address the shift toward personalized immunotherapy, contrasting these methods with the toxicity profiles often seen in traditional chemotherapy.

Beyond the theoretical framework, the session will cover data from the company's clinical trials, including the 331-patient Phase III study for glioblastoma and the ongoing development of DCVax-Direct for inoperable solid tumors. The CancerCare event serves as a platform for dialogue between the company and NHS clinicians, aiming to integrate emerging vaccine technologies into existing cancer care pathways. Following the address, the company intends to publish the full slide deck on its corporate website.